124 related articles for article (PubMed ID: 28978082)
1. Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.
Hay JF; Lappin K; Liberante F; Kettyle LM; Matchett KB; Thompson A; Mills KI
Oncotarget; 2017 Sep; 8(40):67891-67903. PubMed ID: 28978082
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
3. Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.
Young CS; Clarke KM; Kettyle LM; Thompson A; Mills KI
Oncotarget; 2017 Aug; 8(31):51429-51446. PubMed ID: 28881658
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
5. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
6. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
8. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line.
Li X; Guan X; Li F; Chen Y; Li N
J Int Med Res; 2016 Aug; 44(4):882-92. PubMed ID: 27189198
[TBL] [Abstract][Full Text] [Related]
10. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
Prebet T; Vey N
Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat in cutaneous T-cell lymphoma.
Duvic M; Vu J
Drugs Today (Barc); 2007 Sep; 43(9):585-99. PubMed ID: 17940636
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
Morgan SS; Cranmer LD
BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.
Iwamoto M; Friedman EJ; Sandhu P; Agrawal NG; Rubin EH; Wagner JA
Cancer Chemother Pharmacol; 2013 Sep; 72(3):493-508. PubMed ID: 23820962
[TBL] [Abstract][Full Text] [Related]
17. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
